What are the appropriate ondansetron (Zofran) dosages for an 11‑year‑old child, including oral and IV routes?

Ondansetron (Zofran) Dosing for an 11-Year-Old Child

For an 11-year-old child, the appropriate ondansetron dose is 4 mg orally three times daily (every 8 hours) for chemotherapy-induced nausea/vomiting, or 0.15 mg/kg IV (up to 8 mg) for postoperative or acute vomiting. 1

Oral Dosing by Indication

Chemotherapy-Induced Nausea and Vomiting

For moderately emetogenic chemotherapy in children aged 4-11 years:

• 4 mg orally three times daily 1
• First dose: 30 minutes before chemotherapy starts
• Subsequent doses: 4 hours and 8 hours after the first dose
• Continue 4 mg three times daily (every 8 hours) for 1-2 days after chemotherapy completion 1

For children 12 years and older, dosing transitions to adult regimens:

• 8 mg orally twice daily for moderately emetogenic chemotherapy 1

Important caveat: The FDA label explicitly states there is no experience with 24 mg dosing (used for highly emetogenic chemotherapy in adults) in pediatric patients 1

Gastroenteritis-Associated Vomiting

For acute gastroenteritis with vomiting:

• Single dose approach: 0.13-0.26 mg/kg orally has been shown effective 2
• Multidose approach: Recent high-quality evidence demonstrates that providing caregivers with ondansetron to administer at home (in response to ongoing vomiting over 48 hours) reduces moderate-to-severe gastroenteritis by approximately 50% compared to placebo 3
• Weight-based dosing of 0.15-0.2 mg/kg has been validated in multiple studies 2, 4

Intravenous Dosing by Indication

Chemotherapy-Induced Nausea and Vomiting

Standard IV dosing:

• 0.15 mg/kg IV administered three times (at 0,4, and 8 hours) 5, 6
• Maximum single dose: 8 mg 7, 8
• This regimen has demonstrated 56-58% complete response rates in pediatric oncology patients 5, 6

Loading dose approach (for highly emetogenic chemotherapy):

• 16 mg/m² IV (maximum 24 mg) as a loading dose, followed by two doses of 5 mg/m² every 8 hours 9
• This higher-dose regimen has been shown safe in pediatric oncology patients, with severe adverse events occurring in only 0.9% of administrations 9

Postoperative Nausea and Vomiting

Dose-response studies have established:

• 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg IV are all equally effective 10
• 0.05 mg/kg IV is sufficient and as effective as higher doses for PONV prevention 10
• The FDA label does not provide specific pediatric PONV dosing, noting "no experience" with ondansetron orally disintegrating tablets for PONV in children 1

Acute Gastroenteritis (Inpatient Setting)

• 0.2 mg/kg IV as a single bolus has demonstrated significant efficacy 4
• This dose reduced IV rehydration requirements from 39% to 10% and achieved complete cessation of vomiting in 73% of patients 4

Key Clinical Considerations

Route selection:

• Oral formulations (including orally disintegrating tablets) are preferred when the child can tolerate oral intake 1
• IV route is reserved for active vomiting, inability to take oral medications, or perioperative settings 5

Dose-response relationship:

• Within the range of 0.05-0.15 mg/kg IV, higher doses do not provide additional efficacy for PONV 10
• For gastroenteritis, doses between 0.13-0.26 mg/kg orally show similar efficacy without dose-dependent benefits 2

Safety profile:

• Ondansetron is generally well-tolerated in children 6
• Most common adverse events include headache, constipation, and diarrhea in chemotherapy patients 6
• Loading doses up to 16 mg/m² have acceptable safety profiles with severe adverse events rare (0.9%) 9

Common pitfall: Avoid exceeding maximum single doses of 8 mg IV or 16 mg/m² (max 24 mg) for loading doses, as higher doses do not improve efficacy and may increase adverse events 7, 8, 9

Hepatic impairment: In severe hepatic dysfunction, total daily dose should not exceed 8 mg 1